Zeo ScientifiX, Inc. has entered into a strategic partnership with Pluri Inc., a biotechnology company based in Haifa, Israel. This partnership aims to enhance Zeo's manufacturing and commercialization capabilities in the regenerative medicine sector. The agreement, finalized on October 26, 2026, is expected to bolster Zeo's position in the biological products industry, which is known for its rapid innovation and growth.

The partnership involves a license-for-equity transaction, allowing Zeo to utilize Pluri's proprietary 3D cell expansion technology. This technology is crucial for the development and manufacture of cell-based products, which are increasingly important in regenerative medicine, aesthetics, wellness, and longevity markets. The collaboration is designed to expand both companies' reach and effectiveness in these sectors.

Zeo ScientifiX, which operates in the biological products sector (SIC 2836), has a well-established U.S. biologics business. This includes a substantial physician network, dedicated marketing department, and educational programs that support its product offerings. The company’s existing capabilities will serve as a strong foundation for introducing additional products and expanding its commercial operations.

According to the recent SEC filing (accession number 0001829126-26-011800), the partnership agreement outlines several key provisions. Pluri will grant Zeo an exclusive license to manufacture and commercialize its regenerative medicine product portfolio in the U.S. This exclusive license is ongoing, subject to certain conditions, and includes payment of royalties based on net sales.

In addition to the licensing agreement, Zeo will issue shares to Pluri, resulting in Pluri holding 41% of Zeo's outstanding common stock. The partnership also includes provisions for technology transfers, non-competition agreements, and regulatory approvals, ensuring both companies work collaboratively towards mutual goals.

Following the closing of the transaction, Pluri is expected to own 50% of Zeo's outstanding shares. This significant equity stake indicates a strong commitment from Pluri to the partnership and the potential for further collaboration in the future.

The agreement is anticipated to impact various stakeholders, including Zeo's existing shareholders and its network of physicians. By enhancing its product offerings and operational capabilities, Zeo aims to attract more customers and improve its market position. The partnership with Pluri could also prompt competitors in the biological products industry to adapt their strategies in response to Zeo's strengthened capabilities.

As the partnership progresses, further filings may provide additional details on the operational impacts and financial implications of this agreement. For now, the strategic alliance marks a significant step for Zeo ScientifiX as it seeks to expand its influence in the regenerative medicine market.